ReviewThe Biochemical journal2026
The future of Forkhead box O transcription factors.
Review in The Biochemical journal, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Integrated bioinformatics analysis, machine learning, and experimental validation reveal that ACSL1 drives myocardial ischemia reperfusion injury via ferroptosis.Journal of bioenergetics and biomembranes · 2026Article
- Candida-associated immune and metabolic rewiring in chronic obstructive pulmonary disease.BMC pulmonary medicine · 2026Article
- Overexpression of FOXO1 may suppress proliferation and migration and correlate with tumor immune cells in nasopharyngeal carcinoma.Translational cancer research · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The Forkhead box O (FOXO) class of transcription factors is evolutionary conserved both structurally and at least in part also functionally. FOXO activation results in transcriptional programs that provide cellular resilience toward exogenous and endogenous challenges, especially challenges that provoke cellular oxidative stress. This FOXO-dependent mechanism of resilience explains by and large the observed longevity phenotype in model organisms where increased FOXO activity extends lifespan. This may even hold for human lifespan as genome-wide association studies show a strong linkage between FOXO3 and human lifespan. Despite decades of studies on FOXOs, there are still many unresolved questions. Here, we discuss some of these knowledge gaps, related to our general understanding of transcriptional control by FOXOs, the role of the intrinsically disordered regions that constitute over 50% of FOXOs sequence, the role of cellular context in determining isoform specificity, and finally, the importance of resilience in understanding FOXO function. The latter, we think, provides context to the evolutionary role of FOXOs. So, rather than providing an exhaustive summary of literature findings, we focus on some of the omissions in our knowledge of FOXO function. Resolving these outstanding questions, we think, will help to provide the necessary insight to know how and when to manipulate FOXO function in a manner that will contribute to healthy aging.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.